YTHDF2 and colorectal carcinoma: YTHDF2 recognizes and targets m6A-modified GSK-3β mRNA for degradation, enhances β-catenin activity, reduces YTHDF2 expression, inhibits Wnt/β-catenin/Cyclin D1 pathway-related protein expression, leads to G0/G1 phase arrest in cells, and ultimately inhibits CRC cell proliferation [101].